Gabapentin Canon - Instructions For Use, Reviews, Price, 300 Mg, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Gabapentin Canon

Gabapentin Canon: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Use in the elderly
14. 14. Drug interactions
15. 15. Analogs
16. 16. Terms and conditions of storage
17. 17. Terms of dispensing from pharmacies
18. 18. Reviews
19. 19. Price in pharmacies

Latin name: Gabapentin Canon

ATX code: N03AX12

Active ingredient: gabapentin (Gabapentin)

Producer: CJSC "Kanonfarma Production" (Russia)

Description and photo update: 2020-04-07

Prices in pharmacies: from 368 rubles.

Buy

Gabapentin Canon is an antiepileptic drug.

Release form and composition

Dosage form - capsules: hard gelatinous, size No. 0, filled with powder from white to almost white with a yellowish tinge, the formation of lumps is possible, which crumble when pressed slightly; body and cap of capsules - green (10 pcs. in blister strip packs, in a cardboard box 3, 5 or 10 packs; 15 pcs. in blister strip packs, in a cardboard box 2, 4 or 6 packs. Each the package also contains instructions for the use of Gabapentin Canon).

Composition for 1 capsule:

• active substance: gabapentin - 300 mg;
• auxiliary components: calcium hydrogen phosphate dihydrate - 60 mg; potato starch - 32 mg; magnesium stearate - 4 mg; polyethylene glycol-4000 (macrogol-4000) - 4 mg;
• capsule body: gelatin - 58.0055 mg; dye indigo carmine (E132) - 0.0302 mg; dye quinoline yellow (E104) - 0.0203 mg; titanium dioxide - 0.944 mg;
• capsule cap: gelatin - 36.3763 mg; dye quinoline yellow (E104) - 0.0127 mg; dye indigo carmine (E132) - 0.0189 mg; titanium dioxide - 0.5921 mg.

Pharmacological properties

Pharmacodynamics

The active ingredient in Gabapentin Canon is gabapentin, the exact mechanism of its pharmacological action is currently unknown.

In terms of chemical structure, gabapentin is similar to the neurotransmitter gamma-aminobutyric acid (GABA), but its mechanism of action differs from that of valproates, barbiturates, benzodiazepines, GABA transaminase inhibitors, GABA reuptake inhibitors, GABA agonists and prodrugs, and other known substances that interact with GABA. In vitro studies using the labeled radioisotope gabapentin on the brain of rats have revealed new areas of its binding to proteins, including the hippocampus and neocortex. This may explain the anticonvulsant and analgesic activity of gabapentin and its derivatives. It has been reliably established that the site of gabapentin binding is the alpha-2-delta (α-2-δ) subunit of voltage-gated calcium (Ca ²⁺) channels.

In clinically relevant doses, gabapentin does not bind to other common drug receptors and neurotransmitters present in the brain [GABA _B, GABA _A, glutamate, glycine, benzodiazepine and NMDA (N-methyl-D-aspartate) receptors].

In vitro, unlike phenytoin and carbamazepine, gabapentin does not interact with sodium channels. Its use, according to the results of a number of in vitro test systems, led to a partial decrease in the response to the glutamate agonist NMDA, but only if its concentration was more than 100 μmol / L, which is unattainable in vivo. In vitro, the substance slightly reduces the release of monoamine neurotransmitters. In rats, in some areas of the brain, gabapentin, like sodium valproate, increases the metabolic rate of GABA, but its effect is extended to other areas of the brain. The relationship of the various effects of Gabapentin Canon with its anticonvulsant activity has not yet been established. According to the results of animal studies, it was found that gabapentin, easily penetrating into the brain tissue, relieves seizures,caused by chemical convulsants (including inhibitors of GABA synthesis), maximum electroshock, as well as in genetic modeling of convulsive syndromes.

The efficacy and safety of gabapentin was evaluated in a clinical study for the adjuvant therapy of focal seizures in pediatric patients aged 3–12 years. In the gabapentin group, when compared with the placebo group, there were quantitative but statistically insignificant differences in the frequency of a 50% decrease in the number of attacks. In an additional analysis of the response rate to treatment depending on the child's age, which was considered as a continuous variable or divided into two age subgroups (from 3 to 5 years and from 6 to 12 years), there was no statistically significant effect of the patient's age on the effectiveness of gabapentin.

Pharmacokinetics

The main pharmacokinetic characteristics of gabapentin:

• absorption: after oral administration, C _max (maximum concentration) of the substance in the blood plasma is achieved after 2-3 hours (T _Cmax). With an increase in the dose, the bioavailability of gabapentin decreases, taking capsules with a dosage of 300 mg provides an absolute bioavailability of 60%. Foods, including those containing a large amount of fat, as well as repeated administration of the drug, have no clinically significant effect on its pharmacokinetics. In the course of clinical studies, the content of gabapentin in blood plasma varied usually from 2 to 20 μg / ml, this concentration range does not allow predicting the efficacy and safety of Gabapentin Canon;
• distribution: gabapentin does not bind to blood plasma proteins, its volume of distribution (V _d) is 57.7 liters. The level in the cerebrospinal fluid (CSF) in patients with epilepsy is ~ 20% of the C _min (minimum equilibrium concentration) in the blood plasma. During lactation, gabapentin is excreted into breast milk;
• metabolism: in humans, the metabolism of gabapentin has not been studied; it is known that it does not induce nonspecific liver oxidases responsible for the biotransformation of medicinal substances;
• excretion: gabapentin is excreted unchanged exclusively through renal elimination. The half-life (T _1/2) does not depend on the dose taken and averages 5-7 hours.

Pharmacokinetic parameters in the equilibrium state of gabapentin in the human body due to repeated administration at a dose of 300 mg (1 capsule) with an interval of 8 hours: C _max - 4.02 μg / ml; T _Cmax - 2.7 hours; T _1/2 - 5.2 h; AUC _0-8 (area under the concentration-time curve in the period from 0 to 8 hours after taking the drug) - 24.8.

Elimination constant, plasma and renal clearance of gabapentin are directly dependent on creatinine clearance.

Special patient groups:

• elderly patients: a decrease in the plasma clearance of gabapentin associated with age-related deterioration in renal function and other body functions is likely;
• patients with impaired renal function, patients on hemodialysis: since gabapentin is removed from the blood plasma during hemodialysis, it is recommended to adjust its dosage regimen when treating patients of this group;
• Pediatric patients: In children, the pharmacokinetics of gabapentin was studied with the participation of 50 healthy subjects aged 1 month. up to 12 years old. It was revealed that in children over 5 years of age the level of gabapentin in blood plasma is similar to that in adults, provided that the drug is used in an equivalent dose, calculated in mg / kg of body weight. In 24 healthy children aged 1–48 months. AUC values were approximately 30% lower; C _max values are lower, and clearance is higher than in children over 5 years old and in adult patients.

The nonlinearity of the parameters of the pharmacokinetics of gabapentin, including F (bioavailability index) in the calculation, was established, which is associated with a decrease in F with an increase in the dose taken. Elimination rates that do not include F, such as ground clearance and T _1/2, are better described by a linear model. With a single dose of Gabapentin Canon, the equilibrium plasma concentrations of gabapentin are predictable and calculated on the basis of pharmacokinetic data.

Indications for use

Gabapentin Canon is used in the following cases:

• neuropathic pain in adult patients over 18 years of age. The efficacy and safety of the drug for these indications for the treatment of patients under 18 years of age have not been studied;
• partial convulsions with and without secondary generalization in children over 12 years of age and adults - as a monotherapy drug. The efficacy and safety of the drug for these indications for monotherapy in children under 12 years of age have not been studied;
• partial seizures with and without secondary generalization in children over 3 years of age and in adults - as an additional treatment. The efficacy and safety of using the drug for these indications as an additional treatment for children under 3 years old have not been studied.

Contraindications

Absolute:

• children under 3 years of age - as an additional treatment for partial seizures with and without secondary generalization;
• children under 12 years of age - for monotherapy of partial seizures with and without secondary generalization;
• children and adolescents up to 18 years old - for the treatment of neuropathic pain;
• lack of lactase, lactose intolerance, glucose-galactose malabsorption;
• hypersensitivity to gabapentin or auxiliary components in capsules.

With caution, under the close supervision of a specialist, Gabapentin Canon is taken with renal failure, during pregnancy and breastfeeding.

Gabapentina Canon, instructions for use: method and dosage

Gabapentin Canon capsules are taken orally, regardless of the diet and diet.

If it is necessary to reduce the dose, discontinue the drug or replace it with an alternative drug, this is done gradually, for at least 1 week.

For the treatment of neuropathic pain in adults, the drug is prescribed in an initial daily dose of 900 mg, divided into 3 doses of 1 capsule Gabapentin Canon 300 mg. In case of insufficient effect, it is recommended to gradually increase the dose to a maximum of 3600 mg. But it must be borne in mind that when using the drug in a daily dose above 1800 mg, additional efficacy was not observed.

Therapy of neuropathic pain can be started immediately with a daily dose of 900 mg (3 times a day, 1 capsule), or during the first 3 days, the daily dose can be increased to 900 mg gradually according to the following scheme: first day - 300 mg once a day; the second day - 300 mg 2 times a day; the third day - 300 mg 3 times a day.

Therapy for partial seizures in epilepsy is usually long-term. The dose of Gabapentin Canon is determined by the attending physician, taking into account the patient's individual tolerance of gabapentin and clinical efficacy. To avoid the resumption of seizure activity, the maximum interval between doses should not be more than 12 hours.

For adults and children over 12 years of age, the effective daily dose ranges from 900 to 3600 mg. You can start the course with 300 mg 3 times a day or increase the daily dose according to the scheme: first day - 300 mg 1 time per day; the second day - 300 mg 2 times a day; the third day - 300 mg 3 times a day. In the future, it can be increased to a maximum of 3600 mg per day (4 capsules 3 times a day). Gabapentin Canon is well tolerated in daily doses up to 4800 mg.

When treating children aged 3 to 12 years, the initial daily dose is determined at the rate of 10-15 mg / kg, it is divided into 3 equal doses per day and gradually increased to an effective dose for about 3 days. The effective daily dose for children depends on age and is: 5 years and older - 25–35 mg / kg, divided into 3 equal doses; from 3 to 5 years - 40 mg / kg, divided into 3 equal doses. With prolonged use, children tolerate gabapentin well in daily doses up to 50 mg / kg.

There is no need to control the concentration of the substance in the blood plasma. Gabapentin Canon can be used as part of complex treatment with other anticonvulsants. In this case, it is not necessary to take into account the change in its plasma level or the content of other anticonvulsant substances in the serum.

In patients in serious condition, for example, with low body weight, after organ transplantation, etc., a slower increase or use of lower doses, or an increase in the intervals before their increase, is required.

In case of renal failure, it is recommended to reduce the dose of Gabapentin Canon, depending on the creatinine clearance (CC), according to the following scheme:

• CC more than 80 ml / min - daily dose 900–3600 mg;
• CC 50–79 ml / min - daily dose 600–1800 mg;
• CC 30–49 ml / min - daily dose 300–900 mg;
• CC 15-29 ml / min - daily dose 150-600 mg;
• CC less than 15 ml / min - daily dose 150-300 mg.

The daily dose should be divided into three equal doses.

With a CC of 29 ml / min or less, 300 mg of gabapentin is prescribed every other day.

For patients with CC less than 15 ml / min, the daily dose is reduced in proportion to the indicator, for example, with CC = 7.5 ml / min, half of the dose obtained with CC = 15 ml / min is prescribed.

Patients on hemodialysis who have not previously taken gabapentin are recommended to prescribe a saturating dose of 300-400 mg. With reduced renal function in patients undergoing dialysis, the maintenance dose is selected in accordance with QC. It is recommended to take 200–300 mg of gabapentin after every 4 hours of hemodialysis.

Side effects

The distribution of system-organ side effects by frequency of occurrence corresponds to the following gradation: very often - more than 0.1; often - from 0.01 to 0.1; infrequently - from 0.001 to 0.01; rarely - from 0.0001 to 0.001; extremely rare - less than 0.0001; the frequency is unknown - side effects were observed during the post-registration use of Gabapentin Canon, therefore, based on the incoming data, it is impossible to calculate the frequency reliably. When the frequency category was different, the side effect was assigned a higher category across studies.

Adverse reactions observed in clinical studies in the treatment of epilepsy (monotherapy with gabapentin or a combination with other anticonvulsants) or neuropathic pain:

• infections and infestations: very often - viral lesions; often - pneumonia, respiratory tract infection, urinary tract infection, other types of infections, otitis media;
• blood and lymphatic system: often - leukopenia; frequency unknown - thrombocytopenia;
• immune system: infrequently - hypersensitivity reactions, including urticaria; the frequency is unknown - systemic reactions (fever, rash, hepatitis, eosinophilia, lymphadenopathy, etc.);
• metabolism and nutrition: often - anorexia, increased appetite;
• psyche: often - hostility, depression, confusion, anxiety, impaired thinking, nervousness, emotional lability; infrequently - mental deterioration; frequency unknown - hallucinations;
• nervous system: very often - dizziness, drowsiness, ataxia; often - convulsions, dysarthria, hyperkinesia, amnesia, insomnia, tremor, headache, impaired sensitivity (paresthesia, hypesthesia), nystagmus, impaired coordination, increased / weakened / lack of reflexes; infrequently - hypokinesia; rarely - loss of consciousness; frequency unknown - other movement disorders (choreoathetosis, dyskinesia, dystonia);
• organ of vision: often - disturbances of visual perception (amblyopia, diplopia);
• organ of hearing and labyrinthine disorders: often - vertigo; frequency unknown - tinnitus;
• myocardium: infrequently - palpitations;
• vascular system: often - symptoms of vasodilation or hypertension;
• respiratory system, chest and mediastinal organs: often - shortness of breath, pharyngitis, bronchitis, cough, rhinitis;
• digestive tract: often - constipation or diarrhea, dryness of the mucous membrane of the mouth or pharynx, flatulence, dyspepsia, abdominal pain, nausea, vomiting, gingivitis, dental disease; frequency unknown - pancreatitis;
• hepatobiliary system: frequency unknown - hepatitis, jaundice;
• skin and subcutaneous tissues: often - facial edema, purpura (most often manifested by bruising that occurs during physical injury), skin rash, itching of the skin, acne; frequency unknown - Stevens-Johnson syndrome, erythema multiforme, angioedema, alopecia, drug-induced skin rash, including eosinophilia and systemic reactions;
• musculoskeletal and connective tissue: often - arthralgia, myalgia, back pain, muscle twitching; frequency unknown - myoclonus, rhabdomyolysis;
• urinary system: frequency unknown - urinary incontinence, acute renal failure;
• genitals and mammary gland: often - impotence; frequency unknown - gynecomastia, breast enlargement, sexual dysfunction (including changes in libido, ejaculation disorder, anorgasmia);
• general disorders: very often - fever, fatigue; often - peripheral edema, asthenia, general malaise, gait disturbance, pain of various localization, flu-like syndrome; infrequently - generalized edema; frequency is unknown - withdrawal syndrome (the most common symptoms are nausea, anxiety, insomnia, pains of various localization, hyperhidrosis), chest pain; during therapy, cases of unexplained sudden death were reported, the relationship of which with gabapentin intake has not been established;
• data from laboratory and instrumental studies: often - a decrease in the level of leukocytes, an increase in body weight; infrequently - an increase in the activity of ALT (alanine aminotransferase), AST (aspartate aminotransferase) and the concentration of bilirubin in the blood plasma, hyperglycemia; rarely - hypoglycemia (mainly in patients with diabetes mellitus); frequency unknown - hyponatremia, increased activity of CPK (creatine phosphokinase);
• trauma, intoxication and complications of manipulation: often associated with falls, abrasions, injuries, fractures.

The development of acute pancreatitis while taking Gabapentin Canon was reported, but a causal relationship with therapy has not been reliably established.

The development of myopathy with an increase in CPK activity was recorded in patients on hemodialysis with end-stage renal failure.

Respiratory tract infection, otitis media, bronchitis and seizures have only been observed in clinical studies, which also reported aggressive behavior and hyperkinesis in children.

Overdose

A single dose of 49,000 mg gabapentin caused the patient to feel dizzy, double vision, drowsiness, speech impairment, loss of consciousness, lethargy, and mild diarrhea. These symptoms completely disappeared during symptomatic treatment.

It is important to take into account that taking high doses of Gabapentin Canon reduces its absorption in the intestine.

An overdose of gabapentin can contribute to the development of coma, especially if other drugs that suppress the function of the central nervous system are used simultaneously.

Since gabapentin does not bind to plasma proteins, it is cleared during hemodialysis, but experience has shown that the procedure is usually not necessary. Hemodialysis in case of intoxication may be indicated in patients with severe renal failure.

In the course of experiments conducted on mice and rats, gabapentin was administered at doses up to 8000 mg / kg, however, it was not possible to establish its lethal dose when administered orally. Signs of acute intoxication in the experimental animals were ataxia, ptosis, difficulty breathing, hypo- or hyperactivity.

special instructions

Suicidal ideation, suicidal tendencies

Antiepileptic drugs, including gabapentin, can increase the risk of suicidal activity, but the mechanism of its development is unknown. A meta-analysis of randomized, placebo-controlled studies of the effect of antiepileptic drugs found a slight increase in the likelihood of a patient developing suicidal thoughts and suicidal behavior. In this regard, while taking Gabapentin Canon, it is necessary to ensure that the patient is carefully monitored for the development or aggravation of depression, manifestations of suicidal activity, as well as any other changes in behavior. At the first signs of suicidal ideation or behavior, the patient or his caregiver should consult a doctor.

Acute pancreatitis

If acute pancreatitis develops while taking Gabapentin Canon, it is required to evaluate the possibility of discontinuing the drug.

Withdrawal syndrome, increased seizure activity

At the end of treatment with gabapentin, withdrawal symptoms, accompanied by seizures, were not observed. However, abrupt discontinuation of anticonvulsant drugs for epilepsy may trigger the development of status epilepticus. As with therapy with other antiepileptic drugs, while taking gabapentin, an increase in the frequency of seizures or the appearance of another type of seizure is likely.

Attempts to cancel all concomitant anticonvulsants due to the patient's development of resistance to them and switch to gabapentin monotherapy were largely unsuccessful.

It is believed that gabapentin is ineffective in primary generalized seizures, such as absences, and may even exacerbate them in some cases. Therefore, the use of gabapentin for mixed seizures, including absences, requires caution.

Abuse and dependence

Based on the results of post-registration observations, cases of drug abuse and the development of drug dependence on it were established. As with therapy with other drugs that affect the central nervous system, doctors are required to carefully study the history of patients for abuse of gabapentin. It is necessary to find out whether the patient was unreasonably seeking to receive Gabapentin Canon or to increase the dose, whether he developed an immunity to gabapentin.

Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)

During therapy with antiepileptic drugs, including gabapentin, the development of such severe hypersensitivity reactions that threaten the patient's life, such as a drug rash with eosinophilia and systemic symptoms, was observed. It is important to keep in mind that early signs of an allergic reaction, such as swollen lymph nodes or fever, may develop before a skin rash appears. When observing these symptoms, the patient should be examined immediately. In the absence of other reasons, except for taking gabapentin, therapy is canceled.

Laboratory research

During the combined use of gabapentin with other anticonvulsants in the determination of protein in urine using the Ames N-Multistix SG test strips, false positive results were recorded. Therefore, if it is necessary to conduct such analyzes, it is recommended to determine the protein in the urine by a more specific method based on the precipitation of the protein with sulfosalicylic acid.

Effect of gabapentin on the central and peripheral nervous system

Cases of dizziness and drowsiness have been reported with Gabapentin Canon, which increase the likelihood of accidental injury, such as falling. According to post-registration observations, there were reports of confusion, loss of consciousness and impaired mental activity. Patients should be warned about the possibility of such side effects, they should be careful during therapy until the profile of negative reactions is clarified.

Simultaneous use with opioid analgesics increases the level of gabapentin in blood plasma. If necessary, such a complex therapy, the patient is provided with careful monitoring regarding the appearance of symptoms of suppression of the function of the central nervous system, such as sedation, drowsiness, depression of the respiratory center. An appropriate dose reduction of gabapentin or opioid analgesics is required.

Anaphylactic shock

While taking Gabapentin Canon, anaphylaxis may develop, which is characterized by the following symptoms: swelling of the lips, tongue and throat, difficulty breathing, severe arterial hypotension. The condition requires immediate medical attention. Patients should be aware that at the first sign of anaphylaxis, gabapentin should be discontinued and immediate medical attention should be sought.

Influence on the ability to drive vehicles and complex mechanisms

During treatment, patients are not recommended to drive vehicles or complex mechanisms until the absence of a negative effect of Gabapentin Canon on their psychophysical abilities has been confirmed. Gabapentin affects the central nervous system, as a result of which drowsiness, dizziness, confusion or loss of consciousness, and other similar symptoms may develop. They can be dangerous to patients, driving vehicles or complex machinery, and others, even if they are mild / moderate. The likelihood of developing symptoms is increased at the beginning of therapy or with an increase in the dose of gabapentin.

Application during pregnancy and lactation

There is a general risk for pregnant women associated with epilepsy and antiepileptic drugs. The likelihood of having children with congenital malformations in mothers undergoing anticonvulsant therapy increases 2–3 times. The most commonly observed pathologies are cleft upper lip and palate, impaired development of the cardiovascular system, neural tube defects. It has been found that with the simultaneous administration of several antiepileptic drugs, the risk of malformations increases in comparison with monotherapy. During pregnancy, only one anticonvulsant should be used whenever possible.

Women of reproductive age, as well as those potentially fertile, require the advice of a qualified specialist. When planning a pregnancy, it is important to assess the need for anticonvulsant therapy. At the same time, antiepileptic treatment should not be stopped abruptly, as this can provoke a resumption of seizures and cause serious consequences for the mother and child. Sometimes children born to women with epilepsy have developmental delays. But it is not possible to determine exactly whether it is associated with hereditary factors, social reasons, mother's illness or taking anticonvulsants.

It is impossible to reliably determine the risk of taking Gabapentin Canon during pregnancy in humans, since there are no data on its use in pregnant women. In the course of experiments conducted on animals, the toxicity of the substance to the fetus was established.

It has been found that gabapentin is excreted in breast milk, but its effect on the child is unknown.

Gabapentin Canon during pregnancy and breastfeeding is prescribed only for vital indications, provided that the expected benefit to the mother exceeds the possible risk to the fetus / child.

No effect of gabapentin on fertility has been found in animal studies.

Pediatric use

In pediatric practice, the use of Gabapentin Canon is contraindicated: in the treatment of neuropathic pain - in patients under 18 years of age; partial seizures with secondary generalization and without as a monotherapy drug - in children under 12 years of age; partial seizures with secondary generalization and without as an additional treatment - in children under 3 years of age.

The effect of a long (more than 36 weeks) course of gabapentin therapy on a child's ability to learn, intelligence and development has not been adequately studied. For this reason, Gabapentin Canon is prescribed for long-term use only after a comprehensive assessment of the ratio of possible risk and benefit.

With impaired renal function

For patients with renal insufficiency and patients on hemodialysis, the dose of Gabapentin Canon is recommended to be adjusted depending on the CC.

For violations of liver function

Patients with hepatic impairment do not need to adjust the dosage regimen of Gabapentin Canon.

Use in the elderly

Clinical studies of the effect of gabapentin on elderly patients (over 65 years of age) have not been conducted. According to the results of a blind study of the use of the drug for the treatment of neuropathic pain in elderly patients, it was found that drowsiness, peripheral edema and asthenia were observed in them more often than in patients under 65 years of age. Otherwise, the profile of side effects did not differ from that in patients of other age groups.

Due to the age-related decrease in renal function, elderly patients may need to adjust the dose of Gabapentin Canon.

Drug interactions

According to information from the literature, as well as from reports of spontaneous episodes, it became known about respiratory depression and symptoms of sedation associated with the use of opioid analgesics and gabapentin. These adverse reactions have sometimes been associated with the simultaneous use of opioids and gabapentin, especially in elderly patients.

Taking gabapentin at a dose of 600 mg two hours after taking morphine in sustained-release capsules at a dose of 60 mg increased the mean AUC of gabapentin by 44% (compared with gabapentin monotherapy), which is associated with an increase in the pain threshold in response to a cold pressor test. The clinical significance of this change has not been clarified. Pharmacokinetic parameters of morphine did not change, the profile of side effects when taken together with gabapentin did not differ from that in the placebo group. The degree of interaction between these drugs taken at other doses is unknown.

Valproic acid, phenytoin, phenobarbital, carbamazepine do not interact with gabapentin when used simultaneously. In the equilibrium state, the pharmacokinetics of gabapentin in healthy volunteers and patients receiving other anticonvulsants are identical.

Taking gabapentin and oral contraceptives containing norethisterone (ethinyl estradiol) does not change the pharmacokinetics of both drugs.

Simultaneous use with aluminum and magnesium-containing antacids reduces the bioavailability of gabapentin by approximately 24%, so it is recommended to take it no earlier than 2 hours after antacids.

Probenecid has no effect on the renal elimination of gabapentin.

Cimetidine, when taken together with gabapentin, reduces the excretion of the latter by the kidneys by 14%, which probably has no clinical significance.

The simultaneous use of naproxen at a dose of 250 mg and gabapentin at a dose of 125 mg increases the absorption of gabapentin from 12 to 15%. Gabapentin does not affect the pharmacokinetics of naproxen. It should be borne in mind that these doses are less than the minimum therapeutic. The interaction of these drugs in high doses has not been studied.

Analogs

The analogues of Gabapentin Canon are Gapentek, Gabagamma, Gabapentin, Konvalis, Katena, Neurontin, Lepsitin, Tebantin, Egipentin, Eplirontin, etc.

Terms and conditions of storage

Store in secondary packaging (cardboard box) at a temperature not exceeding +25 ° С. Keep out of the reach of children.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Gabapentin Canon

Many patients leave positive reviews about Gabapentin Canon. They note the high efficiency of the drug, the convenient form of release and the mode of administration. The drug relieves severe pains of neuropathic genesis well, but it is advised to take it only after consulting a specialist.

For some patients, the drug did not fit, they complain of side reactions in the form of muscle weakness and a feeling of heaviness in the head.

Price for Gabapentin Canon in pharmacies

The approximate price of Gabapentin Canon 300 mg is 362 rubles. per package containing 50 capsules.

Gabapentin Canon: prices in online pharmacies

Drug name Price Pharmacy

Gabapentin Canon 300mg capsules 50 pcs. 368 RUB Buy

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!